127 related articles for article (PubMed ID: 15780966)
1. Different susceptibility of human immunodeficiency virus type 1 to Env gp41-derived synthetic peptides corresponding to the C-terminal heptad repeat region.
N A PI; Li GM; Warachit J; Iwabu Y; Tsuji S; Auwanit W; Yamamoto D; Goto T; Hayashi Y; Kiso Y; Ikuta K
Microbes Infect; 2005 Mar; 7(3):356-64. PubMed ID: 15780966
[TBL] [Abstract][Full Text] [Related]
2. Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV.
Gustchina E; Hummer G; Bewley CA; Clore GM
J Med Chem; 2005 Apr; 48(8):3036-44. PubMed ID: 15828842
[TBL] [Abstract][Full Text] [Related]
3. Design and evaluation of antiretroviral peptides corresponding to the C-terminal heptad repeat region (C-HR) of human immunodeficiency virus type 1 envelope glycoprotein gp41.
Soonthornsata B; Tian YS; Utachee P; Sapsutthipas S; Isarangkura-na-Ayuthaya P; Auwanit W; Takagi T; Ikuta K; Sawanpanyalert P; Kawashita N; Kameoka M
Virology; 2010 Sep; 405(1):157-64. PubMed ID: 20580393
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain.
Lu L; Tong P; Yu X; Pan C; Zou P; Chen YH; Jiang S
Biochim Biophys Acta; 2012 Dec; 1818(12):2950-7. PubMed ID: 22867851
[TBL] [Abstract][Full Text] [Related]
5. Stronger anti-HIV-1 activity of C-peptide derived from HIV-1 89.6 gp41 C-terminal heptad repeated sequence.
Seo JK; Kim HK; Lee TY; Hahm KS; Kim KL; Lee MK
Peptides; 2005 Nov; 26(11):2175-81. PubMed ID: 15876473
[TBL] [Abstract][Full Text] [Related]
6. The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors.
Gallo SA; Sackett K; Rawat SS; Shai Y; Blumenthal R
J Mol Biol; 2004 Jun; 340(1):9-14. PubMed ID: 15184018
[TBL] [Abstract][Full Text] [Related]
7. Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions.
Nameki D; Kodama E; Ikeuchi M; Mabuchi N; Otaka A; Tamamura H; Ohno M; Fujii N; Matsuoka M
J Virol; 2005 Jan; 79(2):764-70. PubMed ID: 15613304
[TBL] [Abstract][Full Text] [Related]
8. Multimerized CHR-derived peptides as HIV-1 fusion inhibitors.
Nomura W; Hashimoto C; Suzuki T; Ohashi N; Fujino M; Murakami T; Yamamoto N; Tamamura H
Bioorg Med Chem; 2013 Aug; 21(15):4452-8. PubMed ID: 23800723
[TBL] [Abstract][Full Text] [Related]
9. Characterization of HIV-1 resistance to a fusion inhibitor, N36, derived from the gp41 amino-terminal heptad repeat.
Izumi K; Nakamura S; Nakano H; Shimura K; Sakagami Y; Oishi S; Uchiyama S; Ohkubo T; Kobayashi Y; Fujii N; Matsuoka M; Kodama EN
Antiviral Res; 2010 Aug; 87(2):179-86. PubMed ID: 20438763
[TBL] [Abstract][Full Text] [Related]
10. Trimeric heptad repeat synthetic peptides HR1 and HR2 efficiently inhibit HIV-1 entry.
Mzoughi O; Teixido M; Planès R; Serrero M; Hamimed I; Zurita E; Moreno M; Granados G; Lakhdar-Ghazal F; BenMohamed L; Giralt E; Bahraoui E
Biosci Rep; 2019 Sep; 39(9):. PubMed ID: 31477581
[TBL] [Abstract][Full Text] [Related]
11. C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread.
Medinas RJ; Lambert DM; Tompkins WA
J Virol; 2002 Sep; 76(18):9079-86. PubMed ID: 12186891
[TBL] [Abstract][Full Text] [Related]
12. Electrostatically constrained alpha-helical peptide inhibits replication of HIV-1 resistant to enfuvirtide.
Nishikawa H; Nakamura S; Kodama E; Ito S; Kajiwara K; Izumi K; Sakagami Y; Oishi S; Ohkubo T; Kobayashi Y; Otaka A; Fujii N; Matsuoka M
Int J Biochem Cell Biol; 2009 Apr; 41(4):891-9. PubMed ID: 18834950
[TBL] [Abstract][Full Text] [Related]
13. Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120.
Liu S; Lu H; Niu J; Xu Y; Wu S; Jiang S
J Biol Chem; 2005 Mar; 280(12):11259-73. PubMed ID: 15640162
[TBL] [Abstract][Full Text] [Related]
14. The C34 Peptide Fusion Inhibitor Binds to the Six-Helix Bundle Core Domain of HIV-1 gp41 by Displacement of the C-Terminal Helical Repeat Region.
Louis JM; Baber JL; Clore GM
Biochemistry; 2015 Nov; 54(45):6796-805. PubMed ID: 26506247
[TBL] [Abstract][Full Text] [Related]
15. Identification of a human protein-derived HIV-1 fusion inhibitor targeting the gp41 fusion core structure.
Chao L; Lu L; Yang H; Zhu Y; Li Y; Wang Q; Yu X; Jiang S; Chen YH
PLoS One; 2013; 8(5):e66156. PubMed ID: 23741527
[TBL] [Abstract][Full Text] [Related]
16. Determinants of human immunodeficiency virus type 1 baseline susceptibility to the fusion inhibitors enfuvirtide and T-649 reside outside the peptide interaction site.
Heil ML; Decker JM; Sfakianos JN; Shaw GM; Hunter E; Derdeyn CA
J Virol; 2004 Jul; 78(14):7582-9. PubMed ID: 15220433
[TBL] [Abstract][Full Text] [Related]
17. Temperature-dependent intermediates in HIV-1 envelope glycoprotein-mediated fusion revealed by inhibitors that target N- and C-terminal helical regions of HIV-1 gp41.
Gallo SA; Clore GM; Louis JM; Bewley CA; Blumenthal R
Biochemistry; 2004 Jun; 43(25):8230-3. PubMed ID: 15209519
[TBL] [Abstract][Full Text] [Related]
18. A time-resolved fluorescence assay to identify small-molecule inhibitors of HIV-1 fusion.
Dams G; Van Acker K; Gustin E; Vereycken I; Bunkens L; Holemans P; Smeulders L; Clayton R; Ohagen A; Hertogs K
J Biomol Screen; 2007 Sep; 12(6):865-74. PubMed ID: 17644771
[TBL] [Abstract][Full Text] [Related]
19. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients.
Labrosse B; Morand-Joubert L; Goubard A; Rochas S; Labernardière JL; Pacanowski J; Meynard JL; Hance AJ; Clavel F; Mammano F
J Virol; 2006 Sep; 80(17):8807-19. PubMed ID: 16912327
[TBL] [Abstract][Full Text] [Related]
20. Chemoenzymatic synthesis of HIV-1 gp41 glycopeptides: effects of glycosylation on the anti-HIV activity and alpha-helix bundle-forming ability of peptide C34.
Wang LX; Song H; Liu S; Lu H; Jiang S; Ni J; Li H
Chembiochem; 2005 Jun; 6(6):1068-74. PubMed ID: 15883971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
